The rVSVΔG-ZEBOV-GP vaccine was developed by the Public Health Agency of Canada and licensed initially to NewLink Genetics and subsequently to Merck & Co, Inc. A total of 8 phase 1 clinical trials were undertaken and have demonstrated rVSVΔG-ZEBOV-GP to be generally well-tolerated and immunogenic in humans [5] [6] [7] . Based on these studies, 4 large, phase 2/3 clinical trials were initiated to demonstrate safety, immunogenicity, and where possible, efficacy. This randomized, double-blind, multicenter phase 3 clinical trial (NCT02503202) was undertaken to examine the lot-to-lot consistency of rVSVΔG-ZEBOV-GP and provide further safety and immunogenicity data. The observation of a relatively high incidence of arthritis in one of the phase 1 sites prompted us to design the study in such a way that detailed information was collected about the incidence, onset, and duration of arthralgia, arthritis, and rash in a large, well-controlled study [6, 7] . We report here the preplanned, interim 6-month safety analysis.
METHODS

Design
This was a randomized, double-blind, placebo-controlled study conducted at 40 sites in the United States, 1 site in Spain, and 1 site in Canada, between 17 August 2015 and 2 May 2016. A total of 1197 healthy adults were randomized (1194 vaccinated) to receive 1 of 3 consistency lots of rVSVΔG-ZEBOV-GP vaccine (2 × 10 7 plaque-forming units [pfu] ), a high dose of rVSVΔG-ZEBOV-GP vaccine (1 × 10 8 pfu), or placebo in a 2:2:2:2:1 ratio. This would result in 250 subjects in each vaccine group, and 125 subjects in placebo with the targeted total enrollment of 1125 subjects. The study will continue in a subpopulation of subjects among the US sites (N = 565) until 2 years after vaccination to collect long-term safety and immunogenicity data. At the time of writing this manuscript, the glycoprotein enzyme-linked immunosorbent assay (gpELISA) and the plaque-reduction neutralization titer test were still in the process of being validated, and the immunogenicity data of this study will be the subject of a separate manuscript.
Study Procedures
A vaccine report card (VRC) was distributed at visit 1 and reviewed with each subject. Injection-site reactions (including swelling, redness, and pain/tenderness) were recorded daily by the subject from days 1 to 5 postvaccination. Oral temperatures and systemic and/or injection-site adverse events (AEs) were recorded by the subject from days 1 to 42 postvaccination. Arthralgia (joint pain), arthritis (joint swelling), rashes, and vesicular lesions (blisters) were prompted on the VRC to be recorded by the subject from days 1 to 42 postvaccination. From the end of visit 3 (day 42) through visit 4 (month 6), only serious AEs (SAEs) and recurrences of events of arthralgia/arthritis, rash, and/or vesicular lesions were collected. Safety was evaluated for all subjects through 6 months postvaccination, including 42 days of solicited AEs. AE intensity was to be assessed as mild (awareness of sign or symptom, but easily tolerated), moderate (discomfort enough to cause interference with usual activity), or severe (incapacitating with inability to work or do usual activity). Injection-site redness or swelling from the day of vaccination through day 5 postvaccination was evaluated by maximum size.
Subjects who experienced arthralgia, arthritis, rash, or vesicular lesions at any time through 42 days postvaccination were instructed to immediately contact the investigative site. Based on the symptoms, subjects were to be brought back for unscheduled examinations, to potentially include a dermatology or rheumatology consultation, and collection of specimens (synovial fluid, vesicular fluid, and skin biopsies) to be tested for the presence of the vaccine virus via real-time polymerase chain reaction (PCR; details are shown in the Supplementary Materials).
In accordance with principles of Good Clinical Practice, written informed consent was obtained from each participant prior to study entry. Additional consent was obtained for the collection of specimens at the rheumatology/dermatology site. The protocol was approved by the human studies committees at each research site. All study assessments were conducted in a blinded manner; unblinding occurred after database lock.
Population
Healthy subjects 18-65 years old were eligible for the study (inclusion/exclusion criteria are shown in the Supplementary Materials). Participants were advised to avoid pregnancy by means of appropriate contraceptive methods.
Vaccine
The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant vaccine (details are shown in the Supplementary Materials). Vaccine (3 consistency lots of rVSVΔG-ZEBOV-GP vaccine [2 × 10 7 pfu] and 1 lot of high-dose rVSVΔG-ZEBOV-GP vaccine [1 × 10 8 pfu] ) was stored at ≤ -70°C with the vaccine thawed and administered within 15 minutes after thawing. Placebo (0.9% normal saline) was stored at room temperature. Subjects were vaccinated with 1.0 mL of study vaccine/placebo intramuscularly in the deltoid muscle of the nondominant arm using a 3.0-mL polypropylene syringe and 23-gauge needle.
Randomization
A double-blind/masking technique was used. The rVSVΔG-ZEBOV-GP vaccine and placebo were prepared and dispensed by an unblinded pharmacist or qualified trial site personnel. The subject, the investigator, and personnel involved in the vaccine administration or clinical evaluation were blinded. Treatment allocation/randomization occurred centrally using an interactive voice response system using a computer-generated, site-balanced allocation schedule. Treatment allocation/ randomization was stratified according to age (18-45 and 46-65 years) .
Statistical Analysis
All randomized participants who were vaccinated and had safety follow-up were included in the safety analysis and included in the group for the treatment they actually received. The primary safety objective was to determine the safety and tolerability of rVSVΔG-ZEBOV-GP vaccine from 3 consistency lot groups (A, B, and C, each separately and combined) and the high-dose group through 42 days postvaccination. An exploratory objective examined the safety and tolerability for SAEs through 6 months postvaccination.
The AEs and fever profiles were described for the study vaccine after each vaccination and for the entire vaccination period. AEs are summarized with counts, percentages, and, when provided, exact 95% CIs (Clopper-Pearson method). Comparisons of rVSVΔG-ZEBOV-GP to placebo are reported with 95% CIs calculated using the Miettinen and Nurminen method [8] .
Nominal P values were provided for informative purposes, not for hypothesis testing.
All data were fully reviewed, source document verified, and no data queries were outstanding at the time of the database lock. However, as this study is continuing until 2 years postvaccination, data are subject to change pending further information.
Sample Size and Power
The sample size for this study (planned 250 subjects per lot) was determined to show consistency of immunogenicity between the 3 lots of rVSVΔG-ZEBOV-GP with 99% power assuming 10% dropouts; the standard deviation on the log-scale of the gpELISA geometric mean titer (GMT) of 1 (estimated from 3 phase 1 studies); and the true gpELISA GMT ratio between any 2 lots of 1, and equivalence margins of 0.5-fold and 2.0-fold. With a planned sample size of 750 rVSVΔG-ZEBOV-GP (250 × 3 consistency lot groups) and 125 planned placebo subjects, there was 80% power to detect 4% vs 0% AEs, respectively.
RESULTS
Participant Accounting and Demographics
Overall, 1197 subjects were randomized 2:2:2:2:1 to receive either a single vaccination of 1 of 3 consistency lots of rVSVΔG-ZEBOV-GP (2 × 10 7 pfu), a high dose of rVSVΔG-ZEBOV-GP (1 × 10 8 pfu), or placebo. A total of 1194 (99.7%) subjects were vaccinated and 1138 (95.1%) completed the study (Figure 1 ). The reasons for the 56 discontinuations were as follows: lost to follow-up (35), withdrawal (18), death (2) , and physician decision (1) . The baseline characteristics were comparable among groups (Table 1) .
Adverse Events
Safety follow-up information was obtained in 1183 of 1194 (99.1%) vaccinated subjects. Overall, 81%-85% of participants in the vaccine groups reported ≥1 AE postvaccination compared with 44% of placebo recipients (Table 2 ). In general, the proportion of participants reporting injection-site and systemic AEs were higher in the vaccine groups compared to the placebo group and similar between the vaccine groups. The incidence of injection-site related events was 70.8% vs 13.5% and the incidence of systemic AEs was 63.2% vs 35.6% in the vaccine and placebo groups, respectively ( Table 2) . Table 3 displays the proportion of subjects with VRC-prompted injection-site AEs (incidence >0% in ≥1 vaccination group) and Table 4 displays systemic AEs (incidence ≥4 subjects in ≥1 group; day 1 to month 6) that were statistically significantly different in ≥1 vaccine group from placebo. Most of these reports were mild to moderate in intensity. The percentage of subjects in the combined lots group, high-dose group, and placebo group with severe injection site-related events was 2.8%, 2.7%, and 0.0%, respectively, and for severe systemic AEs was 10.3%, 13.5%, and 1.5% respectively (Tables 3 and 4) . Pain was the most frequent reported injection-site related event (up to 70%) and pyrexia the most common systemic event (up to 29%). Fever of any degree postvaccination was more common in the high-dose group (32.2% had fever ≥38.0°C and 4.3% ≥39.0°C) than the combined lots group (20.2% had fever ≥38.0°C and 3.2% ≥39.0°C), and both vaccine groups reported higher rates of fever as compared to the placebo group (0.8% had fever ≥38.0°C and 0.8% ≥39.0°C) ( Table 5 ). All SAEs between day 1 and month 6 after vaccination are presented in Supplementary Table 1 , and all systemic AEs with an incidence ≥2% in ≥1 group between day 1 and month 6 after vaccination are presented in Supplementary  Table 2 .
Rash, Arthritis, and Arthralgia
Higher rates of rash were observed in the combined lots group (3.8%) and high-dose group (3.8%) compared to the placebo group (1.5%), but the differences between groups did not reach statistical significance.
In total, 18 of 1050 (1.7%) cases of arthritis (Medical Dictionary for Regulatory Activities [MedDRA] preferred terms arthritis [n = 15] , monoarthritis [n = 1], osteoarthritis [n = 1], and polyarthritis [n = 1]) were reported in the vaccine group and none in the placebo group. Most subjects with arthritis had ≥1 affected joint (12/18) . Using a broader definition for arthritis by adding the MedDRA preferred terms joint swelling and joint effusion, the number of subjects with arthritis events increased to 51 (4.9%). Arthralgia and arthritis (broader definition) were reported at a statistically higher rate in the vaccine groups than in placebo recipients (Table 6 ). In the combined lots, high-dose, and placebo groups, the incidence of arthralgia was 17.1%, 20.4%, and 3.0%, respectively; and for arthritis was 5.1%, 4.2%, and 0%, respectively.
The onset of arthralgia was usually in the first week postvaccination (median, 2 days), of short duration (median, 3 days), and part of a syndrome of multiple early events such as fever, headache, and myalgia. The onset of arthritis was usually in the second week postvaccination (median, 11 days) with a median duration of 7 days. There was a notable difference in the incidence of arthritis (broader definition) between the age categories 18-45 and 46-65 years. It was most pronounced in the 2 × 10 7 group: 3.3% vs 7.5%, with a 95% CI for the difference (4.2%) of 0.7%-7.8%. The difference in the 1 × 10 8 pfu group was less pronounced (4.0% vs 4.6%). Combining all vaccine groups resulted in an arthritis incidence rate of 3.5% (18-45 years) vs 6.8% (46-65 years) with a 95% CI for the difference (3.4%) of 0.4%-6.3%.
Of 51 subjects with arthritis (broader definition), 8 (16%) also reported rash. One subject also reported dermatitis, and there were no cases of vasculitis. In some subjects with arthralgia/arthritis, rash, and/or vesicular lesions, laboratory samples were collected during the study if symptoms required further investigations.
Mild increases in C-reactive protein were noted in 22 subjects with these symptoms, and elevated alanine aminotransferase levels were observed in 4 subjects.
A total of 16 specimens were collected for the presence of rVSVΔG-ZEBOV-GP vaccine virus by PCR testing: 8 skin biopsies, 4 vesicular fluid, and 4 synovial fluid. Three specimens were positive (1 synovial fluid, 1 skin biopsy, and 1 vesicular fluid), 11 were negative, and 2 had an insufficient amount of sample to test. Details are presented in the Supplementary Materials.
The proportion of subjects reporting SAEs was low across all groups: 2.3% in the combined lots group, 1.2% in the high-dose group, and 0% in the placebo group (Table 2 ). There were no discontinuations due to vaccine-related SAEs.
Five pregnancies were reported during the first 42 days postvaccination. Two subjects were lost to follow-up, 2 subjects gave birth with no AEs or complications reported, and 1 subject had a spontaneous abortion. The estimated date of conception of the latter subject was 5 days postvaccination and the spontaneous abortion occurred 4 weeks after conception. The subject did not see a medical provider for the positive pregnancy test nor for the spontaneous abortion. No further information is available. Two subjects died during the study, both in the combined lots group. Neither death was considered by the investigator to be related to study vaccinations. A 64-year-old woman died of a craniocerebral injury after a fatal fall 152 days postvaccination, and a 47-year-old man died of hepatic failure with an onset 76 days postvaccination. The latter subject was diagnosed 7 years earlier with alcoholic pancreatitis and did not disclose this condition to the study site that inadvertently enrolled this subject in the study.
DISCUSSION
This phase 3, randomized, placebo-controlled clinical trial was designed to assess the safety and immunogenicity of 3 consistency lots (2 × 10 7 pfu) and a high-dose lot (1 × 10 8 pfu) of rVSVΔG-ZEBOV-GP vaccine in 1197 healthy adults. The immunogenicity data are currently not available and will be presented in a separate publication. The rVSVΔG-ZEBOV-GP vaccine was generally well-tolerated. A higher proportion of vaccine recipients than placebo recipients reported local reactogenicity including pain, erythema, and swelling as well as systemic reactogenicity including fever, headache, arthralgia, pain, chills, and fatigue. These events occurred principally during the first few days postvaccination. The proportion of participants reporting injection-site and systemic AEs were similar between all 4 vaccine groups. Pain was the most common local reactogenicity finding, occurring in up to 70% of subjects. Pyrexia was the most common systemic reactogenicity finding, occurring in up to 29% of subjects. The majority of AEs were of mild to moderate intensity and resolved within 1 week; no SAEs were associated with rVSVΔG-ZEBOV-GP vaccination. Arthralgia was reported by 20% of subjects receiving high-dose and 17% of subjects receiving low-dose vaccine. Arthralgia had a median onset within 2 days postvaccination, and lasted for a median of 3 days in the setting with other acute phase AEs such as fever, headache, and myalgia. Arthritis (broader term) was reported by 4.9% of all vaccinated subjects with a median onset of 10-11 days and duration of 5-7 days. Arthritis was reported more commonly in vaccinated subjects 46-65 years of age than subjects 18-45 years of age. Data are presented as No. (%) unless otherwise indicated. All subjects were confirmed to be between 18 and 65 years of age; calculated age may be out of range due to age masking of date of birth. Lot A, B, C = 2 × 10 7 plaque-forming units (pfu); high dose = 1 × 10 8 pfu.
Abbreviations: rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine; SD, standard deviation.
A number of phase 1 studies have reported safety findings in healthy volunteers who received doses of the rVSVΔG-ZEBOV-GP vaccine that ranged from 3 × 10 5 to 1 × 10 8 pfu [5] [6] [7] . Consistent with our findings, the most common AEs were injection-site pain, myalgia, headache, fatigue, fever, and chills. The majority of AEs were mild or moderate in intensity and no serious AEs were associated with rVSVΔG-ZEBOV-GP vaccination. Every subject is counted a single time for each applicable specific injection-site AE. A subject with multiple injection-site AEs within a system organ class is counted a single time for that system organ class. A system organ class or specific injection-site AE appears on this report only if its incidence in 1 or more of the columns is greater than or equal to the percentage of incidence specified in the report title, after rounding. Erythema and swelling are not included in this table because they were measured by size instead of intensity Abbreviations: AE, adverse event; CI, confidence interval; rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine; VRC, vaccine report card. Abbreviations: AE, adverse event; rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine; SAE, serious adverse event.
a Determined by the investigator to be related to the vaccine.
b Study medication withdrawn. Every subject is counted a single time for each applicable specific injection-site AE. A subject with multiple injection-site AE within a system organ class is counted a single time for that system organ class. A system organ class or specific injection-site AE appears on this report only if its incidence in 1 or more of the columns is greater than or equal to the percentage incidence specified in the report title, after rounding.
Abbreviations: AE, adverse event; CI, confidence interval; rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine.
a The most reported verbatim term is "body aches. "
Arthritis was initially identified as an important reactogenicity event in 11 of 51 (22%) of subjects at a World Health Organization (WHO) site in Geneva, where 35 subjects were vaccinated with 1 × 10 7 pfu (18 open-label and 17 placebo-controlled) and 16 were vaccinated with 5 × 10 7 pfu (7 open-label and 9 placebo-controlled) [6, 7] . Of 11 subjects who reported arthralgia, 10 had undergone ultrasound or magnetic resonance imaging. Arthritis was diagnosed based on observed swelling on physical examination or effusion on imaging. Subsequent evaluation of arthritis in subjects vaccinated with 3 × 10 5 pfu (13 open-label and 38 placebo-controlled) indicated that 13 (25%) subjects reported arthralgia, 11 underwent imaging by ultrasound, and 12 (24%) had arthritis confirmed by clinical examination. Such a high proportion of subjects with arthritis was not observed, however, in the other phase 1 studies or at other WHO sites. No cases of arthritis were reported in a double-blind study conducted in the United States of 20 subjects vaccinated with 3 × 10 6 pfu and 20 subjects vaccinated with 2 × 10 7 pfu [5] . One case of arthritis each was reported in Hamburg, Germany, where 20 subjects were vaccinated and Kilifi, Kenya, where 40 subjects were vaccinated (50% at each site vaccinated with 3 × 10 6 pfu and 50% with 2 × 10 7 pfu in an open-label fashion). There were no cases of arthritis observed in Lambaréné (Gabon), where 39 subjects were vaccinated with either 3 × 10 6 pfu (n = 20) or 3 × 10 7 pfu (n = 19) [7] .
The difference between the proportions of subjects reporting arthritis in this study (4.9%) compared to the Geneva study (22.5%) may be due to a more detailed clinical investigation combined with imaging to identify arthritis at the Geneva site, which was not performed in this study. The similar proportion of subjects with arthralgia (17.9%) in this study as described in the Geneva study (23.5%) supports this hypothesis. The median onset and duration of arthritis in this study was similar to the median onset (11 days) and duration (8 days) of arthritis at the Geneva site. The presence of rVSV RNA in synovial fluid in this and the Geneva study indicates seeding of rVSVΔG-ZEBOV-GP vaccine virus into joints. This suggests that at least some of the arthritis observed in this study could be classified as vaccine-induced arthritis. All but 2 subjects with arthritis recovered during the 6 months observation period. Those 2 subjects had existing degenerative osteoarthritis and still experienced some mild joint complaints at month 6. Rash was also reported with some degree of variability across studies. At the Geneva site, of the 11 subjects with arthritis who received either 1 × 10 7 pfu or 5 × 10 7 pfu of the vaccine, 3 (27%) reported a mild maculopapular rash, whereas of the 13 subjects with arthritis who received 3 × 10 5 pfu, 7 (54%) reported skin lesions that included rash [6, 7] . In our study, only 16% of the subjects with arthritis reported rash. The Geneva site also reported an age-dependent Abbreviation: rVSVΔG-ZEBOV-GP, recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine.
a Arthritis includes arthritis, polyarthritis, osteoarthritis, monoarthritis, joint swelling, joint effusion.
b Rash includes rash, rash macular, rash papular, rash vesicular, rash general (this adverse event [AE] was part of the group definition, but did not occur in the study population), petechia, purpura (this AE was part of the group definition, but did not occur in the study population). effect on the incidence of arthritis. However, this was only observed in the low-dose groups (3 × 10 5 pfu) but not in the more comparable high-dose groups (1 × 10 7 or 5 × 10 7 pfu). In this larger study, the increased incidence of arthritis in the older age group (46-65) was observed in both the 2 × 10 7 pfu and 1 × 10 8 pfu groups. Limitations to the interpretation of this study may include the fact that enrollment was restricted to subjects in North America and Europe, rather than Africa, where Ebola outbreaks have occurred and where the rVSVΔG-ZEBOV-GP vaccine is most likely to be utilized in future outbreaks. However, there are a number of ongoing rVSVΔG-ZEBOV-GP studies in Africa that will shed more light on the safety and immunogenicity in the target population such as (1) a [9] [10] [11] [12] . This is the first phase 3 study reporting a detailed safety profile of the clinical 2 × 10 7 pfu rVSVΔG-ZEBOV-GP dose. This is the dose used in the Guinea ring study in which a 100% (95% CI, 74.7%-100.0%) efficacy of the vaccine in preventing Ebola virus disease was observed [10] .
In general, the rVSVΔG-ZEBOV-GP vaccine was welltolerated, with increased rates of injection-site and systemic AEs compared to placebo observed in the lot consistency groups vaccinated with the clinical 2 × 10 7 pfu dose, as well as the group vaccinated with a higher dose of 1 × 10 8 pfu. There were no vaccine-related SAEs observed. The study supports the use of the rVSVΔG-ZEBOV-GP vaccine in persons at risk for Ebola virus disease.
